Auto Fleet Tech Analytics Maintenance Data Company

With a previous background in insurance, the Seller opened this independent agency in 2014 and built it from the ground up. By emphasizing personalized service and trust, there are now 770 policies in force. Eighty-two percent are Medicare Advantage policies, while the other 18 percent are composed of prescription plans, Medicare supplement plans, and dental plans. Only 2 percent are healthcare plans for those under 65. Strategic investments in advertising through radio, TV, and social media have significantly boosted brand recognition, fueling an impressive 65% growth trajectory since 2021. Buyer Qualifications: Potential Buyers must have a direct appointment with Wellcare to be considered. NDA is required to secure the comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

Our client is an exploding, music talent agency--yearly revenue has increased since inception, at a percentage rate year over year of approximately 600%. Our client is a 'positive hustle and hard work ethic' music talent business built on the sheer effort of bringing music artists to the performance stage. Built from the ground up, the business foundation has been developing emerging performance talent while using well-known artists to kick in larger revenue when possible. A great source of success has come from acquiring visas for in-demand international artists and bringing them to the US marketplace. Our client brings the following: - 80+ acts signed to exclusive contracts (1-to-2-year terms) - Robust artist scouting protocol signing on average 3 acts a week - Can be staffed with agents anywhere in the world - Access to the nation's largest contact book of venues, talent buyers, and promoters - Non-exclusive booking rights for Snoop Dogg, Ice Cube, OT Genasis, Xzibit, Warren G, Bizzy Bone, B.o.B, and Bone Thugs N Harmony - Over 1,000 performances booked in half of a calendar year (2022) - Artists in several genres are actively leaving their current booking agencies in favor of coming onto our client's roster. Our client has been awarded positive recognition by a large majority of its artists as well as publications like MoneyGeek, DMC World, Pollstar, Gigwell, and Shoutout Atlanta. The Company's key paradigm is to find and monetize talent. Our client's team is constantly scouting new talent locally and internationally and bringing them to the marketplace. Our client consults on all aspects of artist growth from graphic design and social media strategy to music guidance and consulting. Urgency drives the foundations and operations of Our client's enterprise. This has proven to be a successful strategy, as month over month, our client is showing exceptional growth: in 2022 up to July, the Company is averaging $86,500 per month in gross revenue. NDA is required to secure a comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Growth/Expansion: In CIM. Financing: Seller does not wish to finance. Support & Training: Provided at no charge to enable a smooth transition. Reason for Selling: other projects.

Patented Universal Tumor-Targeting Drug Delivery Platform Co. This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company's ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company's ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to "universally" target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers. The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin. The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations. As the Company's platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI. The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); follwed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company's valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approx. 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support. NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners. Detailed Information Competition: Trying to improve existing therapies and develop novel approaches to hard to treat cancers. Growth & Expansion: Huge market potential. Financing: If the price and deal structure is right. Support & Training: Transition team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

Our client is a world leader in iris recognition technology with a large production capacity based in USA. They are a multinational corporation with a robust track record of selling its best-selling, award winning technology products worldwide. Clients include the UN, the US Department of Homeland Security, US Navy, US Marine Corps, the governments of India the Philippines, Kenya, and in the private Sector Northrop Grumman, InCadence and numerous others. The company has and continues to develop an ever-increasing range of technical applications for its products in a very large and rapidly growing market. Applications range from numerous physical security applications to blockchain and cryptocurrency applications. This firm owns 28 patents (24 registered and 4 pending) for its proprietary "iris matching algorithm, iris recognition in bright outdoors under sunlight" technology and security technology. Our client also has world-leading iris recognition technology to crypto wallet, which dramatically improves the security and convenience of digital assets on blockchain. In addition to multiple patents, our client also owns 10 trademarks. Our client's iris recognition algorithm was evaluated as the world's best technology at IREX I of NIST in the USA, and its excellence has been proven. They are one of few companies to provide a complete solution including SW and HW from iris image scanner to matching SDK on server with the world's best technology. This business has global references for the National ID projects of the Indian and Philippine governments They achieved the No.1 market share, including UN-affiliated organizations such as UNHCR and WFP, and these markets are expanding worldwide. Our client's tech and related device is the only iris camera system satisfying MOSIP SBI 2.0 requirements for authentication (many countries are utilizing the MOSIP platform for their National ID systems). Our client's unique and powerful technologies are registered and protected by global patents, enabling stable business development and expansion. The company offers a total data infrastructure solution (large or small data requirements) for Web 3.0 (Web 3.0 is the approach for a new iteration of the World Wide Web which incorporates concepts such as decentralization, blockchain technologies, and token-based economics). Their technologies are based on Blockchain, IPFS, and distributed storage of private keys (IPFS is a distributed file system that seeks to connect all computing devices with the same system of files. This means data can be securely shared for Know Your Customer and Anti-Money Laundering (KYC and AML) needs. This meets information sharing protocols between service providers and will lead to a new and open data economy. The ramifications are complete security for Bank information, Financial Transaction Data, Driving Data, SNS Contents, Health Information, Government/Education Certification, Insurance Information in short data stemming from virtually any source. Confidential Information Memorandum (CIM) is available upon receipt of our short online NDA. Financing: If the price and deal structure is right. Support & Training: Provided at no charge to enable a smooth transition Reason for Selling: World-wide expansion

Founded in 2011, the Company is a niche consulting and advisory firm serving in cell therapy, gene and gene-modified cell therapies, other regenerative medicines, tissue engineering, and cell-based drug discovery. The company's core focus is to improve cell & gene therapy innovations by providing consulting services for improving business strategy and achieving major regulatory milestones for companies. The Company has created a one-stop shop for all aspects of cell therapy and gene therapy, including quality checks, regulatory meetings, and submissions with the help of leading experts worldwide. The leadership has a unique combination of experience in the academic, biotech industry, government/FDA, and consulting. They serve biotech, pharma companies, consulting services for healthcare providers, subcontracts for other consulting firms, and contracts with government organizations, which enables them to have 6x+ growth in net income from 2019 2021, i.e., $179,000 to $1,095,000 with the help of 110+ customers served over the past six years. The Company's plan is to consummate a transaction with a supportive growth partner in order to accelerate the company's cell and gene therapy market growth by interacting with industry, academia, government, and other international stakeholders in cell & gene therapies and cell-based drug discovery. NDA is required to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: Has headquarters in US contractors operate nationwide / portable / buyer can be located worldwide. Competition: A few competitors in the space are in the field but the Company provides best in class services for its respective niche(s). Growth & Expansion: Continually grow and become more profitable with the help of experts that supports preclinical, clinical, and commercial advisory in the manufacturing, regulatory affairs, Quality/GxP, and M&A arenas. Financing: If the price and deal structure is right. Support & Training: Long term transition, Seller wishes to smooth the transition to maximize success with the Company post-closing and spearhead continued growth. Reason for Selling: Growth.

This established LLC is offering its proprietary organic dough mixture for sale. A trademark is in place. The creator/owner is a lifelong baker and began experiencing health-related gut issues, as millions of people do. In response, she embarked on a research journey and sourced products from everywhere possible to make a perfect 100% clean, plant-based, organic pizza dough. She wanted to provide pesticide-free dough that could last longer in the fridge, that could take the heat without burning to a crisp and could be boiled, fried, baked, and grilled. She created a dough that could be used every day, in a variety of ways, that wouldn't make you sick. In other words, eating clean, organic dough like the Europeans! Thus, the Company was born! Currently offered in over 300 grocery stores, in both frozen and dry mixes, in a variety of flavors, at a very competitive price point. NDA is required to secure a comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information: organic yeast, no chemicals Facilities: none Not applicable with this book. Competition: Other health food-based dough mixes that typically are not organic and sell at a higher price point. Growth & Expansion: Unlimited room for expansion and growth in brick-and-mortar stores, as well as online sales and wholesale opportunities. Financing: TBD if structure and terms are acceptable. Royalties are of interest. Support & Training: To ensure a smooth transition and ongoing success the Sellers will work with a buyer as needed for three months, as an on-call consultant, or as negotiated. The seller will introduce the current production/packaging vendor relationship. Reason for Selling: The Seller has developed and runs another business, and is looking to focus her efforts there.

As technology has become and will continue to become a driving factor within economies worldwide, the marketplace for Value Added Resellers (VARs) is growing at an astounding rate with an expected CAGR of 10% Year-over-Year through the year 2028. What makes VARs necessary within the business landscape - most large and medium-sized Companies do not order enough volume for purchasing direct from a manufacturer and can benefit from purchasing from a go-between such as a VAR, thereby creating a strong need for participants within the marketplace who function as a go-between within a B2B environment. For a VAR to maintain a livelihood and grow within this highly competitive marketplace, Resellers must have access to attractively priced goods from manufacturers, resellers, and wholesalers, and the necessary technologies to help streamline business and ensure that pricing opportunities are not overlooked (on the part of the VAR and their customer). The firms which can capture most and/or all sales within the Reseller industry will be the firms who will prevail in the years to come, ideally those who have the capability for: -Displaying a high capacity for tech solutions and customizations -An abundance of data analysis and KPIs -Sales and marketing -Quoting and sourcing -and overall Integrations and customizations Since opening its doors nearly 20 years ago this Company has created a software solution for quoting, procurement, discounting, a vast array of KPIs, and a content library that in sum is yet to be rivaled by other firms in the space. By creating the necessary relations with only the most optimal suppliers for maintaining a reputation of quality while maintaining an outstanding profit margin, it is these factors while developing strategies and sales channels that the Company has been able to boast $3MM-$4MM in gross sales in its pre-covid year. With their most recent integrations (within the last 1-2 years) the Company is NOW able to harness the expected growth within the reseller space and is expecting a massive adoption of this technology among the resellers who are aware of the demand and the impact of tech integration with these capabilities Key Investment Considerations: o Over $10M investment into the platform development, o 5000+ Tech resellers serviced, o $32B of transactions in the last 3 Years, o Presence in the US, CA, IN, SL o Full-fledged India Center with Development, QA, Marketing, and Sales team o Development team in Sri Lanka o 55%+ profitability over the last 3 years o Cloud native SaaS platform o Turnkey system and solid foundation for growth o Robust growth potential and strategies that have been clearly defined and identified by the Seller o Strong customer and referral base years of premium service offering leading reputation for quality products and pricing o 20+ years in the making o Strong process for instilling R&D and maintaining an elevated level of Quality Control o Robust and unique one-of-a-kind content library The Company and brand are very well established and only need a directed effort related to marketing and the Company can far exceed past sales levels. With proper marketing and underbidding on available contracts there are massive growth opportunities available to a new Owner. NDA is required to secure a comprehensive Confidential Information Memorandum (CIM).

Our client sources an excellent quality bourbon that has a higher yield than a traditional 6-8-year aged bourbon. Due to the higher yield because of less evaporation, they are able to keep the MSRP very competitive and are growing rapidly. They partner with a smaller craft distillery as their co-packer in order to keep production costs down. The founder is a rising, Tennessee-based singer/songwriter with thousands of followers. He uses, and will continue to use, his social media and concerts to publicize the bourbon and allows fans to become partial minority owners of the brand, thus far garnering approximately $200,000 as of the beginning of December 2022. Since the launch of the bourbon brand in 2018 it has earned some of the largest and most prestigious awards which can be awarded in the spirit industry. 1) Named Top 6 in the World in Forbes 2) Featured in Billboard, Rolling Stone, Uproxx, American Songwriter 3) Platinum Los Angeles 4) Double Gold San Francisco (largest award in the world for whiskey to earn) 5) Double Gold New York International 6) Double Gold New York Best Fifty 7) Gold Las Vegas 8) Silver Denver Our client has created a supportive community of real fans who love both the founder's music and the bourbon. Our client has taken the brand as far as 26 states. They will soon expand into Canada and exporting to South Africa & Vietnam is on the horizon. The founder and his partner are willing to stay on the team to bring the Bourbon brand to a much higher national level with a well-capitalized strategic buyer or owner-operator who is passionate about the bourbon industry. An NDA is required to secure a comprehensive Confidential Information Memorandum (CIM). Growth & Expansion: In CIM - NDA Required. Financing: If the price and deal structure is right Support & Training: Provided at no charge to enable a smooth transition Reason for Selling: Other Projects